Investment Rating - The report assigns a "Leading" investment rating to the pharmaceutical industry as of October 31, 2025 [1] Core Insights - The eleventh batch of centralized procurement has seen significant price reductions, but the overall impact on the companies may be limited. The fourth quarter is expected to bring catalysts that could improve investor sentiment [4] - The report highlights that the pharmaceutical sector has experienced a notable price correction, but the fundamentals remain strong, with an anticipated stabilization in investment sentiment due to upcoming catalysts such as academic conferences and favorable policies [4] Summary by Sections Industry Performance - The Hang Seng Index rose by 2.2% during the week of October 22-29, 2025, while the Hang Seng Healthcare Index fell by 0.9%, ranking 12th among 12 industry indices [4][10] - Sub-industry performance varied, with CXO up by 4.6% and biopharmaceuticals down by 2.3% [4][10] Company Valuation Overview - A detailed valuation table lists various companies with their respective ratings, target prices, and earnings projections for FY25E and FY26E, indicating a generally bullish outlook with multiple "Buy" ratings [3] Institutional Holdings - As of October 28, 2025, the proportion of domestic institutional holdings in the pharmaceutical sector decreased slightly to 21.9%, while foreign holdings remained stable [36][39] - Domestic investors have shown a preference for increasing positions in medical device companies and "AI + healthcare" concepts, while foreign investors have focused on long-term potential in innovative drug companies [39][41] Procurement Insights - The eleventh batch of centralized procurement included 55 drug products, with a selection rate of 57%. The report notes that the impact on the overall revenue of selected companies is expected to be minimal [8][9] - The report identifies specific companies and the number of products selected in the procurement process, indicating a limited revenue contribution from these selections [8][9]
十一批集采降幅较大但影响或有限,4Q板块催化剂有望改善投资情绪
BOCOM International·2025-10-31 14:02